Dendritic cell renal cell carcinoma fusion vaccine
/ Beth Israel Deaconess Medical Center
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
April 03, 2024
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
(clinicaltrials.gov)
- P1/2 | N=38 | Completed | Sponsor: Beth Israel Deaconess Medical Center | Active, not recruiting ➔ Completed
Trial completion • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2
January 25, 2023
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
(clinicaltrials.gov)
- P1/2 | N=38 | Active, not recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Dec 2022 ➔ Jul 2023
Trial completion date • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2
February 01, 2022
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
(clinicaltrials.gov)
- P1/2 | N=38 | Active, not recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Dec 2021 ➔ Dec 2022
Trial completion date • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2
March 03, 2021
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
(clinicaltrials.gov)
- P1/2; N=38; Active, not recruiting; Sponsor: Beth Israel Deaconess Medical Center; Trial completion date: Dec 2020 ➔ Dec 2021
Clinical • Trial completion date • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2
December 25, 2020
"https://t.co/qycg5DcrcC"
(@CharuAggarwalMD)
January 30, 2020
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
(clinicaltrials.gov)
- P1/2; N=38; Active, not recruiting; Sponsor: Beth Israel Deaconess Medical Center; Trial completion date: Dec 2019 ➔ Dec 2020
Trial completion date • CSF2
September 07, 2019
Renal cell carcinoma in children and adolescent, a retrospective analysis of a cooperative European cohort
(ECP 2019)
- "TFE3-FISH analysis is the gold standard for MiTRCC diagnosis and should be systemically performed. NGS analysis is ongoing on non-MiTRCC in order to better classify this heterogeneous group."
Retrospective data
1 to 7
Of
7
Go to page
1